Clinical Trial: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors

U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07269145) titled 'A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors' on Nov. 26.

Brief Summary: This is the first-in-human clinical study of TQB3122, aiming to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3122 in advanced solid tumors, and to preliminarily explore its efficacy in solid tumors.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Advanced Cancer

Intervention: DRUG: TQB3122 Capsules

TQB3122 Capsules is a poly(ADP - ribose) polymerase 1 (PARP1) -targeted inhibitor.

Re...